The Effectiveness of Titanium-Prepared Platelet-Rich Fibrin on Angiogenic Biomarkers in Gingival Crevicular Fluid

Chronic Periodontitis Clinical Trial

— T-PRF  

Official title:

The Effect of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) Treatment on the Angiogenic Biomarkers in Gingival Crevicular Fluid (GCF) in Infrabony Defects of Patients With Chronic Periodontitis: A Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02692079
• Other study ID #: 2014/18
• Status: Completed
• Phase: N/A
• First received: February 18, 2016
• Last updated: February 22, 2016
• Start date: February 2014
• Est. completion date: November 2014

Study information

• Verified date: February 2016
• Source: Kirikkale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study investigates the effect of titanium-prepared platelet-rich fibrin (T-PRF) treatment on the angiogenic biomarkers in gingival crevicular fluid (GCF) in infrabony defects of patients with chronic periodontitis. In each patient, the infrabony defect of one side of arch was designated as control group (allograft), while the infrabony defect on the contralateral side of same arch was designated as test group (allograft+T-PRF).

Description:

Platelets are the cells initiating the wound healing and also supporting it by secreting various growth factors actively. These growth factors released by platelets act the increase of connective tissue healing, bone regeneration and repair, fibroblast mitogenesis, wound angiogenesis and the activation of macrophages by stimulating cell proliferation signals.

Titanium-prepared, platelet-rich fibrin (T-PRF), is a new platelet concentrate, is formed in titanium tubes may be more efficient to activate platelets in comparison with glass tubes.The titanium tubes is utilized to refrain any inverse effects of glass tubes and also silica.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: November 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 26 Years to 59 Years

Eligibility

Inclusion Criteria:

• Clinical Diagnosis of Chronic Periodontitis

• The presence of two or three-wall intrabony defects=3 mm deep along with an interproximal probing depth =5 mm after non-surgical periodontal therapy

Exclusion Criteria:

• Systemic illnesses

• Any medications known to affect the outcomes of periodontal surgery

• Pregnancy and lactation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Periodontitis
• Intrabony Periodontal Defect
• Periodontitis

Intervention

Procedure:
• T-PRF
Flap Surgery
• Allograft
Flap Surgery

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kirikkale University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet-derived growth factor-BB (ng/µl) , vascular endothelial growth factor-A (ng/µl), fibroblast growth factor-2 (ng/µl), anjiogenin (ng/µl), angiostatin (ng/µl)		Within the first 30 days after surgery	No
Secondary	The Volume of Gingival Crevicular Fluid (microliter)		Within the first 30 days after surgery	No